Searchable abstracts of presentations at key conferences in endocrinology

ea0026p513 | Bone/calcium/Vitamin D | ECE2011

Influence of thyroid disease in diagnostic accuracy of Tc99m-sestamibi scintigraphy in patients with primary hyperparathyroidism (PHP)

Egana Nerea , Paja Miguel , Gutierrez Maria Teresa , Rodriguez Maria Luisa , Goni Fernando , Ugarte Estibaliz , Espiga Javier

Bilateral cervical exploration has been the gold standard in parathyroid surgery. Nowadays, the preoperative localization procedures have facilitated the minimally invasive surgery. This study aims to analyze the influence of thyroid disease in Tc99m-sestamibi scintigraphy (MIBI) results.A series of 154 patients with PHP who underwent parathyroidectomy was reviewed. Patients were divided into two groups: group 1 (G1, 58 patients) with thyroid diseases, a...

ea0016p808 | Thyroid | ECE2008

Is pre-ablative thyroglobulin useful as a predictor of cure in differentiated thyroid carcinoma?

Paja Miguel , Oleaga Amelia , Perez Josu , Lizarraga Aitzol , Moreno Cristina , Izuzquiza Ana , Goni Fernando

Surgery followed by 131I ablative therapy (IAT) is the usual treatment for patients with differentiated thyroid carcinoma (DTC). Thyroglobulin levels obtained 9–12 months after IAT under TSH stimulation (Tg2) is a very reliable marker for the presence of thyroid tissue. The value of stimulated thyroglobulin previous to ablation (Tg1) is more controversial. The aim of this study was to examine the relationship between Tg1 and Tg2.Material ...

ea0049ep112 | Clinical case reports - Pituitary/Adrenal | ECE2017

Paraganglioma (PG) and cyanotic congenital heart disease (CCHD): the role of tisular hypoxia

Oleaga Amelia , Goni Fernando , Paja Miguel , Ugarte Estibaliz , Moreno Cristina , Iglesias Natalia , Etxeberria Eider , Calles Laura , Dublang Maddalen , Zabalegui Alba

Introduction: CCHD comprises a number of different congenital heart defects associated with elevated pulmonary artery pressure and pulmonary vascular resistance, resulting in a reversed or bidirectional shunt (Eisenmenger syndrome). These entities develop systemic hypoxia. Pheochromocytoma and paraganglioma (PHEO/PG) are neuroendocrine tumours. Several inheritance genetic alterations have been reported in PHEO/PG syndromes. A pathogenic association between these entities is pr...

ea0049ep1040 | Pituitary - Clinical | ECE2017

Radiological study of clinically non-functioning pituitary macroadenomas: a single institutional experience

Moreno Cristina , Paja Miguel , Lizarraga Aitzol , Etxeberria Eider , Arrizabalaga Cristina , Ugarte Estibaliz , Izuzquiza Ana , Goni Fernando , Iglesias Natalia , Calles Laura

Introduction: When facing with non-functioning pituitary macroadenomas (NFPMA), radiological invasion is determinant to surgical approach, apart from histological biomarkers of pituitary tumor aggressiveness (Ki-67; p53 and mitotic index). Invasive tumors usually need additional surgery and/or radiotherapy. There are no much studies describing epidemiological data on aggressive pituitary tumors in clinical practice. We provide information regarding the radiological findings of...

ea0037ep898 | Thyroid cancer | ECE2015

Cytological variants of papillary thyroid carcinoma: clinical presentations according with the presence of BRAF mutation

Oleaga Amelia , Etxeberria Eider , Calles Laura , Goni Fernando , Fuertes Elena , de Ciriza Maite Perez , Ugalde Aitziber , Paja Miguel

Introduction: BRAF(V600E) mutation has received great attention to improve risk stratification in patients with PTC. Its prognostic value in the different Cytological variants (CytV) of PTC is not well established. The aim of this study was to investigate differences in clinicopathological features according to CytV, among patients harbouring the mutation.Methods: We evaluated 102 patients with pathological diagnosis of PTC. All of them underwent total t...

ea0032p1126 | Thyroid cancer | ECE2013

BRAF V600E mutation in papillary thyroid cancer: clinical and pathological features. Is there any role in tailoring initial treatment?

Oleaga Amelia , Goni Fernando , Paja Miguel , Iglesias Natalia , Fuertes Elena , Lizarraga Aitzol , Palacios Angel Gomez , Elorza Ramon

Introduction: BRAF (V600E) mutation is the most frequent detected genetic change in papillary thyroid cancer (PTC) and its presence has been related to aggressive clinical and pathological features. Lymph node metastases (LNMx) are common in PTC and are associated with an increase in loco-regional recurrence. However, prophylactic lymph node dissection is not routinely performed because of high rate of surgery complications. Therefore, there is a need to find a good marker to ...

ea0063p369 | Thyroid 1 | ECE2019

Impact of thyroid autoimmunity on obstetric and perinatal outcomes in pregnant women with subclinical hypothyroidism

Oleaga Amelia , Jimenez-Telleria Patricia , Goni Fernando , Moreno Cristina , Arrizabalaga Cristina , Izuzquiza Ana , Espiga Javier , Martinez Adela , Zabalegui Alba , Paja Miguel

Introduction: Maternal clinical thyroid disorders can cause reproductive complications. However, the effects of mild thyroid dysfunction are controversial. The impact of SH and thyroid autoimmunity on miscarriages, obstetric and perinatal outcomes are not yet well established and the effect of levothyroxine replacement in pregnant women with SH is unclear. The aim of this study was to evaluate the impact of thyroid autoimmunity in early pregnancy on obstetric and perinatal out...

ea0035p1118 | Thyroid Cancer | ECE2014

Clinical and biochemical characteristics of papillary thyroid cancer according to the presence of BRAF (V600E) mutation

Oleaga Amelia , Goni Fernando , Ciriza Miguel Paja1, Maite Perez de , Etxeberria Eider , Calles Laura , Ugarte Estibaliz , Ugalde Aitziber , Elorza J Ramon

Introduction: BRAF (V600E) mutation is the most frequent detected genetic change in papillary thyroid cancer (PTC). Its presence has been related to aggressive clinical and pathological features. Therefore, BRAF mutation has drawn considerable interest as a potential prognostic factor for PTC. The presence of the mutation confers the tumour a disability to uptake RAI, diminishing the therapeutic tools. However if this feature is related to some kind of tumour dedifferentiation...